Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company
Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024
Cash position of
Management hosting conference call and webcast today at
"We believe that Relmada's clinical programs are poised to achieve meaningful, near-term value inflection points. Our lead product candidate, REL-1017, is in a registrational Phase 3 program as a potential adjunct treatment for major depressive disorder. Two ongoing trials, Reliance II and Relight, have been designed to build on positive Phase 2 results, with enhanced site selection and more stringent patient enrollment criteria," said
Upcoming Anticipated Milestones
- Reliance II Interim Analysis Expected by YE 2024
- Initiate Enrollment in the REL-P11 Program by YE 2024
Third Quarter 2024 Financial Results
- Research and development expense for the three months ended
September 30, 2024 , totaled$11.1 million , compared to$10.4 million for the three months endedSeptember 30, 2023 , an increase of$0.7 million . The increase was primarily driven by an increase in study costs associated with the ramp up of the Reliance II/302 and Relight/304 studies in 2024. - General and administrative expense for the three months ended
September 30, 2024 , totaled$11.9 million compared to$12.2 million for the three months endedSeptember 30, 2023 , a decrease of approximately$0.4 million . The decrease was primarily driven by a decrease in stock-based compensation expense. - The net loss for the three months ended
June 30, 2024 , was$21.7 million , or$0.72 per basic and diluted share, compared with a net loss of$22.0 million , or$0.73 per basic and diluted share, for the three months endedSeptember 30, 2023 .
Nine Month Ended
- Research and development expense for the nine months ended
September 30, 2024 , totaled$35.2 million , compared to$40.1 million for the nine months endedSeptember 30, 2023 , a decrease of$4.9 million . The decrease was primarily driven by a decrease in study costs associated with the completion of two Phase 3 trials and the long-term, open-label, safety trial (Study 310) in 2023. - General and administrative expense for the nine months ended
September 30, 2024 , totaled$29.6 million compared to$36.8 million for the nine months endedSeptember 30, 2023 , a decrease of approximately$7.2 million . The decrease was primarily driven by a decrease in stock-based compensation expense. - Net cash used in operating activities for the nine months ended
September 30, 2024 , totaled$43.0 million compared to$41.4 million for the nine months endedSeptember 30, 2023 . - The net loss for the nine months ended
September 30, 2024 , was$61.3 million , or$2.03 per basic and diluted share, compared with a net loss of$73.6 million , or$2.45 per basic and diluted share, for the nine months endedSeptember 30, 2023 . - As of
September 30, 2024 , the Company had cash, cash equivalents, and short-term investments of approximately$54.1 million , compared to cash, cash equivalents, and short-term investments of approximately$96.3 million atDecember 31, 2023 . The company believes its cash balance is adequate to support planned operations through key near-term milestones, into 2025. - The Company had 30,174,202 common shares outstanding, as of
November 4, 2024 .
Conference Call and Webcast Information:
Relmada will host a conference call and webcast today at
A replay of the webcast will be available in the "Investors" section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About REL-1017 and the Phase 3 Program
REL-1017 is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Relmada is developing REL-1017 as a rapid-acting, oral, once-daily adjunctive treatment for major depressive disorder (MDD). The clinical program includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302, NCT04855747) and Relight (Study 304, NCT06011577). The studies are designed to evaluate the safety and efficacy of REL-1017. The primary endpoint of each study is the change in the Montgomery-Asberg Depression Rating Scale (MADRS10) at Day 28.
About REL-P11
Relmada acquired the development and commercial rights to a novel psilocybin and derivatives program in July of 2021. Psilocybin has neuroplastogen™ effects that have the potential to ameliorate neurodegenerative conditions. Relmada identified the potential to use low dose psilocybin as a treatment for metabolic diseases and published the data at the
About
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects", "anticipates", "believes", "will", "will likely result", "will continue", "plans to", "potential", "promising", and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the Reliance-OLS (study 310) to accurately reflect the results of the ongoing Reliance II (study 302) and Relight (study 304) blinded, randomized and controlled studies of REL-1017, failure of the planned Phase 1 and Phase 2a trials for REL-P11, the Company's low-dose, modified release formulation of psilocybin, to be successfully carried out, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the
Investor Contact:
Tim@LifeSciAdvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
|
Condensed Consolidated Balance Sheets |
|
|||||||
|
|
|
|||||||
|
|
|
As of |
|
|
|
|
||
|
|
|
|
|
|
As of |
|
||
|
|
|
2024 |
|
|
|
|
||
|
Assets |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
1,483,789 |
|
|
$ |
4,091,568 |
|
|
Short-term investments |
|
|
52,633,938 |
|
|
|
92,232,292 |
|
|
Prepaid expenses |
|
|
1,584,803 |
|
|
|
1,185,057 |
|
|
Total current assets |
|
|
55,702,530 |
|
|
|
97,508,917 |
|
|
Other assets |
|
|
21,975 |
|
|
|
43,125 |
|
|
Total assets |
|
$ |
55,724,505 |
|
|
$ |
97,552,042 |
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies (See Note 8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,345,541 |
|
|
$ |
3,506,009 |
|
|
Accrued expenses |
|
|
5,741,220 |
|
|
|
8,688,791 |
|
|
Total current liabilities |
|
|
8,086,761 |
|
|
|
12,194,800 |
|
|
Stock appreciation rights |
|
|
12,562 |
|
|
|
- |
|
|
Total liabilities |
|
|
8,099,323 |
|
|
|
12,194,800 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Equity: |
|
|
|
|
|
|
|
|
|
Class A convertible preferred stock, authorized, none issued and outstanding |
|
|
- |
|
|
|
- |
|
|
Common stock, and 30,099,203 shares issued and outstanding, respectively |
|
|
30,174 |
|
|
|
30,099 |
|
|
Additional paid-in capital |
|
|
669,819,907 |
|
|
|
646,229,824 |
|
|
Accumulated deficit |
|
|
(622,224,899) |
|
|
|
(560,902,681) |
|
|
Total stockholders' equity |
|
|
47,625,182 |
|
|
|
85,357,242 |
|
|
Total liabilities and stockholders' equity |
|
$ |
55,724,505 |
|
|
$ |
97,552,042 |
|
|
Condensed Consolidated Statements of Operations (Unaudited) |
|
|||||||||||||||
|
|
|
|||||||||||||||
|
|
|
Three months ended |
|
|
Nine months ended |
|
||||||||||
|
|
|
|
|
|
|
|
||||||||||
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Research and development |
|
$ |
11,149,136 |
|
|
$ |
10,454,072 |
|
|
$ |
35,175,531 |
|
|
$ |
40,055,287 |
|
|
General and administrative |
|
|
11,859,702 |
|
|
|
12,238,566 |
|
|
|
29,639,951 |
|
|
|
36,817,686 |
|
|
Total operating expenses |
|
|
23,008,838 |
|
|
|
22,692,638 |
|
|
|
64,815,482 |
|
|
|
76,872,973 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(23,008,838) |
|
|
|
(22,692,638) |
|
|
|
(64,815,482) |
|
|
|
(76,872,973) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expenses) income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest/investment income, net |
|
|
856,478 |
|
|
|
1,321,441 |
|
|
|
2,875,379 |
|
|
|
3,892,478 |
|
|
Realized (loss) gain on short-term investments |
|
|
147,835 |
|
|
|
(51,714) |
|
|
|
334,082 |
|
|
|
(718,422) |
|
|
Unrealized (loss) gain on short-term investments |
|
|
278,555 |
|
|
|
(579,147) |
|
|
|
283,803 |
|
|
|
72,329 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (expense) income – net |
|
|
1,282,868 |
|
|
|
690,580 |
|
|
|
3,493,264 |
|
|
|
3,246,385 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(21,725,970) |
|
|
$ |
(22,002,058) |
|
|
$ |
(61,322,218) |
|
|
$ |
(73,626,588) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per common share – basic and diluted |
|
$ |
(0.72) |
|
|
$ |
(0.73) |
|
|
$ |
(2.03) |
|
|
$ |
(2.45) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding – basic and diluted |
|
|
30,174,202 |
|
|
|
30,099,203 |
|
|
|
30,160,242 |
|
|
|
30,099,203 |
|
|
Condensed Consolidated Statements of Stockholders' Equity |
|
|||||||||||||||||||
|
|
|
|||||||||||||||||||
|
|
|
Three and Nine months ended |
|
|||||||||||||||||
|
|
|
Common Stock |
|
|
Additional |
|
|
Accumulated |
|
|
|
|
||||||||
|
|
|
Shares |
|
|
Par Value |
|
|
Capital |
|
|
Deficit |
|
|
Total |
|
|||||
|
Balance – December 31, 2023 |
|
|
30,099,203 |
|
|
$ |
30,099 |
|
|
$ |
646,229,824 |
|
|
$ |
(560,902,681) |
|
|
$ |
85,357,242 |
|
|
Stock-based compensation |
|
|
- |
|
|
|
- |
|
|
|
8,295,468 |
|
|
|
- |
|
|
|
8,295,468 |
|
|
Options exercises for common stock |
|
|
74,999 |
|
|
|
75 |
|
|
|
246,672 |
|
|
|
- |
|
|
|
246,747 |
|
|
ATM Fees |
|
|
- |
|
|
|
- |
|
|
|
(25,000) |
|
|
|
- |
|
|
|
(25,000) |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(21,828,126) |
|
|
|
(21,828,126) |
|
|
Balance – March 31, 2024 |
|
|
30,174,202 |
|
|
|
30,174 |
|
|
|
654,746,964 |
|
|
|
(582,730,807) |
|
|
|
72,046,331 |
|
|
Stock-based compensation |
|
|
- |
|
|
|
- |
|
|
|
7,213,419 |
|
|
|
- |
|
|
|
7,213,419 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(17,768,122) |
|
|
|
(17,768,122) |
|
|
Balance – June 30, 2024 |
|
|
30,174,202 |
|
|
|
30,174 |
|
|
|
661,960,383 |
|
|
|
(600,498,929) |
|
|
|
61,491,628 |
|
|
Stock-based compensation |
|
|
- |
|
|
|
- |
|
|
|
7,949,125 |
|
|
|
- |
|
|
|
7,949,125 |
|
|
ATM Fees |
|
|
- |
|
|
|
- |
|
|
|
(89,601) |
|
|
|
- |
|
|
|
(89,601) |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(21,725,970) |
|
|
|
(21,725,970) |
|
|
Balance – |
|
|
30,174,202 |
|
|
$ |
30,174 |
|
|
$ |
669,819,907 |
|
|
$ |
(622,224,899) |
|
|
$ |
47,625,182 |
|
|
|
|
|||||||||||||||||||
|
|
|
Three and Nine months ended |
|
|||||||||||||||||
|
|
|
Common Stock |
|
|
Additional |
|
|
Accumulated |
|
|
|
|
||||||||
|
|
|
Shares |
|
|
Par Value |
|
|
Capital |
|
|
Deficit |
|
|
Total |
|
|||||
|
Balance – December 31, 2022 |
|
|
30,099,203 |
|
|
$ |
30,099 |
|
|
$ |
602,517,138 |
|
|
$ |
(462,110,935) |
|
|
$ |
140,436,302 |
|
|
Stock-based compensation |
|
|
- |
|
|
|
- |
|
|
|
11,354,466 |
|
|
|
- |
|
|
|
11,354,466 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(26,321,576) |
|
|
|
(26,321,576) |
|
|
Balance – March 31, 2023 |
|
|
30,099,203 |
|
|
|
30,099 |
|
|
|
613,871,604 |
|
|
|
(488,432,511) |
|
|
|
125,469,192 |
|
|
Stock-based compensation |
|
|
- |
|
|
|
- |
|
|
|
11,169,517 |
|
|
|
- |
|
|
|
11,169,517 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(25,302,954) |
|
|
|
(25,302,954) |
|
|
Balance – June 30, 2023 |
|
|
30,099,203 |
|
|
|
30,099 |
|
|
|
625,041,121 |
|
|
|
(513,735,465) |
|
|
|
111,335,755 |
|
|
Stock-based compensation |
|
|
- |
|
|
|
- |
|
|
|
11,392,938 |
|
|
|
- |
|
|
|
11,392,938 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(22,002,058) |
|
|
|
(22,002,058) |
|
|
Balance – |
|
|
30,099,203 |
|
|
$ |
30,099 |
|
|
$ |
636,434,059 |
|
|
$ |
(535,737,523) |
|
|
$ |
100,726,635 |
|
|
Condensed Consolidated Statements of Cash Flows |
|
|||||||
|
|
|
|||||||
|
|
|
Nine months ended |
|
|||||
|
|
|
|
|
|||||
|
|
|
2024 |
|
|
2023 |
|
||
|
Cash flows from operating activities |
|
|
|
|
|
|
||
|
Net loss |
|
$ |
(61,322,218) |
|
|
$ |
(73,626,588) |
|
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
23,458,012 |
|
|
|
33,916,921 |
|
|
Realized (gain) loss on short-term investments |
|
|
(334,082) |
|
|
|
718,422 |
|
|
Unrealized (gain) loss on short-term investments |
|
|
(283,803) |
|
|
|
(72,329) |
|
|
Change in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Other receivable |
|
|
- |
|
|
|
512,432 |
|
|
Prepaid expenses and other assets |
|
|
(378,596) |
|
|
|
1,188,309 |
|
|
Accounts payable |
|
|
(1,160,468) |
|
|
|
(2,405,184) |
|
|
Accrued expenses |
|
|
(2,947,571) |
|
|
|
(1,641,475) |
|
|
Stock appreciation rights compensation |
|
|
12,562 |
|
|
|
- |
|
|
Net cash used in operating activities |
|
|
(42,956,164) |
|
|
|
(41,409,492) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
Purchase of short-term investments |
|
|
(11,424,986) |
|
|
|
(57,151,963) |
|
|
Sale of short-term investments |
|
|
51,641,225 |
|
|
|
99,864,149 |
|
|
Net cash provided by investing activities |
|
|
40,216,239 |
|
|
|
42,712,186 |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
|
Proceeds from options exercised for common stock |
|
|
246,747 |
|
|
|
- |
|
|
ATM Fees |
|
|
(114,601) |
|
|
|
- |
|
|
Net cash provided by financing activities |
|
|
132,146 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
Net increase /(decrease) in cash and cash equivalents |
|
|
(2,607,779) |
|
|
|
1,302,694 |
|
|
Cash and cash equivalents at beginning of the period |
|
|
4,091,568 |
|
|
|
5,395,905 |
|
|
Cash and cash equivalents at end of the period |
|
$ |
1,483,789 |
|
|
|
6,698,599 |
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid during the period for: |
|
|
|
|
|
|
|
|
|
Interest |
|
$ |
- |
|
|
$ |
- |
|
|
Income Tax |
|
$ |
- |
|
|
$ |
- |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update-302299382.html
SOURCE
